2
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Alteration of the Agouti Mouse Coat Color Pattern by Bromoergocryptine. Possible Involvement of MSH

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In the Agouti mice C3H A" the coat color of the dorsum changes from birth to maturity. In young animals the dorsal tegument is yellow whereas in adult mice it shifts to dark gray. The administration of bromoergocryptine, a dopamine agonist, as a single injection in a beeswax pellet prevented the color change resulting in the persistence of the immature pattern. After plucking an area of the dorsum of an adult animal, the regrown hair was dark; however, when bromoergocryptine was administered at the time of plucking the new hair was not dark but yellow. When MSH was injected in adult animals previously treated with the drug, the ‘bleaching’ effect of bromoergocryptine was abolished, suggesting that this substance did not act directly upon melanin synthesis. In bromoergocryptine-treated mice the MSH content of the pars intermedia was decreased and the ultrastructure of this lobe contained cells with signs of hypoactivity. These two observations suggested that the effect of the drug on the coat color might be ascribed to inhibition of the secretion of MSH.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1979
          1979
          26 March 2008
          : 29
          : 6
          : 391-398
          Affiliations
          Centro de Estudios Endócrinos and Instituto de Embriología, Biología e Histología, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata
          Article
          122950 Neuroendocrinology 1979;29:391–398
          10.1159/000122950
          522971
          © 1979 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          Original Paper

          Comments

          Comment on this article